These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23422913)

  • 1. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.
    Prince WT; Ivezic-Schoenfeld Z; Lell C; Tack KJ; Novak R; Obermayr F; Talbot GH
    Antimicrob Agents Chemother; 2013 May; 57(5):2087-94. PubMed ID: 23422913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections.
    Stryjewski ME; Potgieter PD; Li YP; Barriere SL; Churukian A; Kingsley J; Corey GR;
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5476-83. PubMed ID: 22869571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
    Huang DB; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Desplats E; Torres A
    Int J Antimicrob Agents; 2018 Aug; 52(2):233-240. PubMed ID: 29783024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections.
    Noel GJ; Draper MP; Hait H; Tanaka SK; Arbeit RD
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5650-4. PubMed ID: 22908151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections.
    Sader HS; Biedenbach DJ; Paukner S; Ivezic-Schoenfeld Z; Jones RN
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1619-23. PubMed ID: 22232289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.
    O'Riordan W; McManus A; Teras J; Poromanski I; Cruz-Saldariagga M; Quintas M; Lawrence L; Liang S; Cammarata S;
    Clin Infect Dis; 2018 Aug; 67(5):657-666. PubMed ID: 29518178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).
    Overcash JS; Kim C; Keech R; Gumenchuk I; Ninov B; Gonzalez-Rojas Y; Waters M; Simeonov S; Engelhardt M; Saulay M; Ionescu D; Smart JI; Jones ME; Hamed KA
    Clin Infect Dis; 2021 Oct; 73(7):e1507-e1517. PubMed ID: 32897367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study.
    Bhatia A; Mastim M; Shah M; Gutte R; Joshi P; Kumbhar D; Periasamy H; Palwe SR; Chavan R; Bhagwat S; Patel M; Llorens L; Friedland HD
    J Assoc Physicians India; 2020 Aug; 68(8):30-36. PubMed ID: 32738837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.
    Friedland HD; O'Neal T; Biek D; Eckburg PB; Rank DR; Llorens L; Smith A; Witherell GW; Laudano JB; Thye D
    Antimicrob Agents Chemother; 2012 May; 56(5):2231-6. PubMed ID: 22314524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Scott LJ
    Drugs; 2020 Aug; 80(12):1247-1258. PubMed ID: 32666425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
    Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
    Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
    Giordano PA; Pogue JM; Cammarata S
    Clin Infect Dis; 2019 Apr; 68(Suppl 3):S223-S232. PubMed ID: 30957167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.
    Paukner S; Sader HS; Ivezic-Schoenfeld Z; Jones RN
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4489-95. PubMed ID: 23836172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1.
    Huang DB; O'Riordan W; Overcash JS; Heller B; Amin F; File TM; Wilcox MH; Torres A; Dryden M; Holland TL; McLeroth P; Shukla R; Corey GR
    Clin Infect Dis; 2018 Apr; 66(8):1222-1229. PubMed ID: 29281036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial.
    Li JZ; Willke RJ; Rittenhouse BE; Rybak MJ
    Surg Infect (Larchmt); 2003; 4(1):57-70. PubMed ID: 12744768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Corey GR; Wilcox MH; Talbot GH; Thye D; Friedland D; Baculik T;
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv41-51. PubMed ID: 21115454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis.
    Monteagudo-Martínez N; Solís-García Del Pozo J; Nava E; Ikuta I; Galindo M; Jordán J
    Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1477-1489. PubMed ID: 32981375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.
    Nichols RL; Graham DR; Barriere SL; Rodgers A; Wilson SE; Zervos M; Dunn DL; Kreter B
    J Antimicrob Chemother; 1999 Aug; 44(2):263-73. PubMed ID: 10473234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
    Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Wilcox MH; Corey GR; Talbot GH; Thye D; Friedland D; Baculik T;
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv53-iv65. PubMed ID: 21115455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.